Surgeons are busy and time is money. Why would a surgeon want to mess with a cumbersome tool involving radioactive materials without an FDA label that going to all this trouble will provide a bona fide survival benefit to the patient?
Survival benefit has been shown in the prior trial, and it is common sense that if a surgeon finds additional tumors there should be a survival benefit. It will be up to cancer foundations to educate the patients to demand the test.
Market Data 
Markets 
AI
